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Abstract: This review focuses on the burden of respiratory syncytial virus (RSV) infection in preterm infants with and 
without chronic lung disease (bronchopulmonary dysplasia, BPD). The year-to-year and seasonal variations in RSV activ-
ity are key aspects of RSV epidemiology, and knowledge/monitoring of local RSV activity is mandatory for guidance of 
prophylaxis with the monoclonal antibodies palivizumab and in the near future motavizumab. Morbidity expressed in 
rates of hospitalizations attributable to RSV illness revealed a mean of 10 percent in preterm infants without and 19 per-
cent (p=0.016) with BPD. Mortality rates diverged widely, and case fatality rates have been reported to range from 0 to 12 
percent. The typical clinical picture of lower respiratory tract infection is not different in term and preterm infants, but 
rates of apnoeas are significantly increased in preterms, ranging from 4.9 to 37.5 percent with decreasing rates observed in 
more recent studies. Until a RSV vaccine is developed and will be available, prophylaxis with palivizumab is the only 
preventative strategy other than hand hygiene and contact measures that significantly reduces RSV hospitalization rates in 
preterm infants both with and without BPD.  
Keywords: Bronchopulmonary dysplasia, monoclonal antibodies, palivizumab, preterms, preventative strategy. 
INTRODUCTION 
  Respiratory syncytial virus (RSV) is the most important 
cause of lower respiratory tract infection in infants and chil-
dren. Fifty to 90 percent of hospitalizations for bronchiolitis, 
5 to 40 percent of those for pneumonia, and 10 to 30 percent 
of those for tracheobronchitis are caused by RSV [1]. Sub-
stantial increases in the number of admissions for RSV bron-
chiolitis (up to 126.300 hospitalizations and 500 deaths an-
nually) have been documented in North America [2]. In 
Canada, inpatient care of RSV illness costs $ 18 million (US 
dollars) yearly, accounting for 62 percent of the total cost of 
this disease [1]. The magnitude of the costs is understand-
able, since virtually all children become infected with RSV 
within two years after birth, and one percent requires hospi-
talization [3].  
  In developed countries, there are well-defined high-risk 
groups, generally with chronic underlying disorders, in 
whom infection with RSV is more likely to progress into 
severe lower-respiratory-tract infections. Healthy infants 
younger than 3 months old are also susceptible to such infec-
tions. High risk groups for severe RSV disease include in-
fants below six months of age, premature infants with or 
without chronic lung disease (bronchopulmonary dysplasia – 
BPD), infants with hemodynamically significant congenital 
heart disease (CHD), immunosuppressed patients (including  
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those undergoing chemotherapy, bone-marrow and solid-
organ transplantation, and those with underlying disorders of 
cellular immunity) or cystic fibrosis, and infants with neu-
romuscular diseases [4-6]. There is no particular age-group 
that is not at risk for RSV infection, but certain risk factors 
have been implicated in more severe disease:low socioeco-
nomic status, crowded living conditions, exposure to indoor 
smoke pollution, a family history of asthma or atopy, and 
perhaps infection with the A subgroup of RSV [4]. Preterm 
infants with or without BPD and infants with CHD are also 
known to be at increased risk for hospitalization including 
admission to an intensive care unit (ICU), ventilatory sup-
port, or prolonged supplemental oxygen [7-9].  
  This review focuses on the burden of RSV disease in 
preterm infants with and without BPD. 
SEASONAL DISTRIBUTIONS OF RSV RELATED 
HOSPITALIZATIONS OF PRETERM INFANTS  
  The year-to-year and seasonal variations in RSV activity 
are key aspects of RSV epidemiology. RSV is a seasonal 
virus, with peak rates of infection occurring annually in the 
cold season in temperate climates, and in the rainy season, as 
temperatures fall, in tropical climates [4].  Among Europe 
RSV related re-hospitalizations of preterm infants show a 
seasonal distribution mainly during the winter and spring 
months ranging from October to May, and peaking between 
December/January and March [9-14]. The distribution of 
hospitalizations and ICU admissions related to confirmed 
RSV infection throughout the study period (IRIS study) 
peaked in December and January [14] and the distribution of 
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extended from October to May, with 29 cases (75.7%) oc-
curring between January and March [10]. The Austrian RSV 
29-32 Study Group including 863 infants aged 29 to 32 
weeks of gestational age revealed 18% of RSV related re-
hospitalizations occurring outside the typical RSV season 
[11]. An even higher rate has been reported by Duppenthaler 
et al., [15] during the 1999/2000 RSV season in Switzerland 
with 36% of hospitalisations occurring after April 1, 2000 
that would not have been preventable by palivizumab pro-
phylaxis initiated in November 1. Overall there are major 
differences between regions throughout the northern hemi-
sphere [16-22]. In the southern hemisphere, for example in 
Gambia, RSV activity peaked during the summer months 
between August and September over a 4-year (1993 – 1996) 
period [23].  
  Thus, knowledge about local RSV epidemics is manda-
tory for targeted prophylaxis with palivizumab in high-risk 
infants. In Austria an epidemiological monitoring system has 
been established in 2002 called RSV-hotline incorporating 
data of infants hospitalized due to RSV disease that are en-
tered into the system voluntarily by Austrian pediatricians 
(https://hc4you.hcsolutions.at/rsv). The seasonal distribu-
tions of RSV attributed hospitalizations of preterm infants in 
Austria over the seasons 1998 to 2001 and 2001 to 2003 are 
shown in Fig. (1a, b), respectively [11, 24]. 
CLINICAL FEATURES OF RSV INFECTION IN 
PRETERM INFANTS 
  The most common infection caused by RSV is of the 
upper respiratory tract; such infections are characterised by 
rhinitis, cough, and sometimes fever. Acute otitis media oc-
curs in up to a third of children with RSV illness; both RSV 
and bacterial pathogens have been isolated from the middle 
ears of children with RSV. Croup also occurs with RSV in-
 
Fig. (1) (a). Seasonal distribution of rehospitalisations due to respiratory illness (proven RSV and non-RSV infections) in premature infants 
of 29–36 weeks gestational age [24]. (b). Seasonal distribution of RSV hospitalizations (n=38) in premature infants of 29–32 weeks’ gesta-
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fection, but bronchiolitis and pneumonia are the most com-
mon manifestations in children. Signs of upper-respiratory-
tract involvement commonly precede those of the lower res-
piratory tract by a few days, and fever, when present, is usu-
ally low grade. Dyspnoea, lower chest-wall indrawing, and 
difficulty in feeding characterise lower-respiratory-tract in-
fection. In bronchiolitis, wheeze may be audible with or 
without a stethoscope, and a prolonged expiratory phase and 
crackles are characteristic. Air trapping results in very fast 
breathing and a palpable liver and spleen. The typical radio-
graphic pattern includes hyperinflation with diffuse intersti-
tial markings and peribronchial thickening. Segmental 
atelectasis, which usually clears spontaneously, is often seen. 
Children with pneumonia, on the other hand, have fine 
crackles and a radiographic pattern of alveolar, segmental, or 
lobar consolidation.  
  Severe bronchiolitis may lead to acute respiratory failure 
associated with severe bronchospasm, moderate to severe 
hypoxia, and carbon dioxide retention. With lung function 
tests [25] two patterns of severe disease are seen: in about 
two-thirds of cases there is obstructive small airways disease 
(bronchiolitis), and in the remainder there is a restrictive 
pattern (pneumonia). Most of the latter cases meet the crite-
ria for acute respiratory distress syndrome. They tend to be 
younger, have more predisposing underlying disease, and are 
ventilated for longer. In severely ill children, complications 
include pulmonary hypertension and cardiovascular com-
promise requiring inotropic support [26].  
  Although bacterial superinfection is rare in developed 
countries, it is more common in developing countries. This 
may partly explain the higher fatality rates seen in develop-
ing nations [4]. Over a five years period we observed a gen-
eral low total rate of bacterial co-infection of 1.9% excluding 
ICU patients [27]. The risk of concurrent bacterial infection 
in preterm infants hospitalized due to respiratory syncytial 
virus infection was three times higher compared to term in-
fants (9.5 vs. 3.1%, p=0.017) and associated with prolonged 
hospitalisation and ICU admission). The predominant patho-
gens were Streptococcus pneumoniae and Haemophilus in-
fluenzae. Mean length of stay in preterm infants with bacte-
rial co-infection was 22.3 days compared to 10.3 days with-
out bacterial co-infection (p < 0.006). 
  Apnoea tends to occur in infants under 2 months of age 
with atelectasia on chest radiography [28] and is common in 
those born prematurely. In cases of severe apnoea, mechani-
cal ventilation may be necessary, despite the absence of res-
piratory failure. The pathophysiology of this manifestation is 
unknown, but postulated mechanisms include the immaturity 
of the respiratory centre in the brain-stems of premature in-
fants, and RSV associated hypersensitivity of the laryngeal 
chemoreceptors [4]. In a recent systematic review the inci-
dence of apnoea including a study population of 5575 hospi-
talized patients with RSV ranged from a high of 23.8% to a 
low of 1.2% [29]. Comparison of the cohort by term and 
preterm birth revealed an expected excess in apnoea inci-
dence in preterms, even in the absence of information about 
chronologic age In detail, the authors cite five of seven stud-
ies reporting on the incidence of apnoea with significant 
rates comparing term to preterm infants (range 0.5 – 12.4% 
compared to 4.9 – 37.5%, respectively, overall p<0.001), see 
Table 1 [29]. A study by Gleeson et al., [30] examined the 
hypothesis that dysregulation of mucosal immune responses 
to respiratory infections is a critical event, which could be 
causal in respiratory arrest of some previously healthy in-
fants. The salivary IgA and IgM concentrations in the appar-
ent life threatening event (ALTE) infants at presentation to 
hospital indicated that a significant mucosal immune re-
sponse had already occurred with nearly 60% of the IgA 
concentrations significantly above the population-based ref-
erence ranges. This hyper-immune response was most evi-
dent in the ALTE infants with pathology evidence of an in-
fection; and the most prevalent pathogen identified was RSV 
(64%). The group compromised 26 infants with a gestational 
age ranging from 26 to 41 weeks at a median age of 60 days. 
Table 1.  Incidence of RSV Associated Apnea by Term ( 37 
Weeks’ Gestation) Versus Preterm Birth [29] 
Study   Term   Preterm   p-value 
Simon et al.,  2007  0.6% 4.9% <  .001 
Willwerth et al., 2006  0.5%  9.9%   < .001 
Bergstrasser et al., 1998  6.7%  17.6%   NS 
Meert et al., 1990  4.0%  5.3%   NS 
Church et al., 1984  11.2%   33.7%   < .001 
Colditz et al., 1982  5.1%  32.1%   < .001 
Bruhn et al., 1977   12.4%   37.5%   < .001 
From: Ralston S, Hill V Incidence of apnea in infants hospitalized with respiratory 
syncytial virus bronchiolitis: a systematic review. J Pediatr 2009; 155:728-33 [29]. 
  Encephalopathy associated with respiratory syncytial 
virus infection is not well recognized. Ng et al., [31] reported 
on an incidence of 1.8% in a total of 487 patients with respi-
ratory syncytial virus bronchiolitis studied over a period of 
four years with seizures being the presenting complication. 
Interestingly, three of the nine infants showing neurologic 
complications had a history of prematurity (27, 28, and 31 
weeks of gestational age, respectively). 
  During a five-year period (1984 to 1989) Meert et al., [7] 
reported on 484 previously healthy infants (including 27% 
preterm born) admitted to the hospital with RSV infection. 
No differences were found in the presenting symptoms of 
respiratory distress, cough, fever or shock, although the pre-
term group was more likely to present with apnea (13 vs. 
4%, p<0.001). Chest roentgenograms revealed that preterm 
infants had a higher incidence of atelectasis/infiltrate and 
hyperinflation (47 vs. 36%, p<0.05, and 28 vs. 19%, p<0.05, 
respectively). Preterm infants had longer hospital stays 
(mean 5.4 vs. 3.6 days, p<0.001) as well as a higher Physiol-
ogic Stability Index and Therapeutic Intervention Score (6.4 
vs. 4.3, p<0.001, and 7.4 vs. 5.4, p<0.001, respectively). 
They were also more likely to receive supplemental oxygen 
(39 vs. 19%), ICU admission (13 vs. 4%), mechanical venti-
lation (12 vs. 2%), and nothing by mouth status (17 vs. 7 %, 
for all p<0.001, respectively). There was no difference in 
postnatal age (mean 5.5 vs. 5.1 months), but preterm infants 
had a younger postconceptual age (mean 3.9 vs. 5.0 months, 
p<0.05). 138    The Open Microbiology Journal, 2011, Volume 5  Resch et al. 
  The 37 preterm infants with RSV related rehospitalisa-
tion of the Munich RSV study [10] presented with pneumo-
nia with and without clinical signs of obstructive bronchitis 
(27%); obstructive bronchitis, bronchiolitis, or acute bron-
chitis (67.6%) or acute upper airway infection (5.4%).  
MORBIDITY AND MORTALITY DUE TO RSV IN-
FECTION IN PRETERM INFANTS WITH AND 
WITHOUT BRONCHOPULMONARY DYSPLASIA 
Morbidity 
  The risk for RSV related hospitalization is significantly 
increased in preterm infants. In East Denmark the incidence 
of RSV infection requiring hospitalization among infants <6 
months was estimated to be 34/1000/season, and was 
32/1000/season among term infants and 66/1000/season 
among preterm infants (p<0.001) [8]. In Southern Austria we 
observed an incidence of RSV infection requiring hospitali-
zation of 6/1000/season among term and 12/1000/season 
(p<0.05) among preterm infants [32]. 
  Why are preterm infants at increased risk for severe RSV 
lower respiratory tract infection? The main factors include 
small lung volumes, a reduced lung surface area, small air-
ways and an increased air space wall thickness [33]. This is 
reflected by the developmental stage of the fetal lungs show-
ing the canalicular period between 16 and 26 weeks followed 
by the saccular period from 26 to 36 weeks and at least the 
alveolar period from 36 to 41 weeks of gestational age. For 
example, the lung volume and surface area of a term are 
three times larger compared to a 30 week preterm infant. 
Additionally, the airways of preterm infants have been venti-
lated mechanically and been suctioned and thus been dam-
aged by many microtraumas with disruption of endothelial 
surfaces enabling pathogens easier to invade. At least the 
immune system of preterm infants is immature resulting in 
low antibody titers (incomplete diaplacentar transfer of ma-
ternal antibodies) and a reduced cellular immunity with re-
duced virus clearance [34]. 
  Groothuis [35] first reported on the increased risk of pre-
term infants with bronchopulmonary dysplasia (BPD) for 
RSV related prolonged hospitalizations, high rates of admis-
sion to the ICU and the need for mechanical ventilation. 
Early data from the PICNIC study group including twelve 
paediatric tertiary care centers during the 1989 to 1990 sea-
son observed 12.6% of hospitalized infants with RSV infec-
tion having chronic lung disease and 23.9% being born pre-
maturely [36]. Another data from the PICNIC study group 
found underlying illnesses including chronic lung disease 
like bronchopulmonary dysplasia significantly associated 
with prolonged hospital stay attributable to RSV compared 
with those who were premature or younger than 6 weeks of 
age on admission [37]. The proportion of infants with under-
lying illness was 22.6% in a study population of 689 pa-
tients, 16% were admitted to ICU and 9.1% needed me-
chanical ventilation. The mortality rates varied across all 
groups, and the rate was 0.9% in the total study population 
 Joffe  et al., [38] reported on a median length of stay for 
RSV disease in preterm infants< 37 weeks gestational age of 
4 days. Infants who were discharged from the NICU and re-
hospitalized during the same RSV season tended to have 
longer admissions than those discharged before the begin-
ning of the season, and they also required more days of oxy-
gen therapy, had a higher risk for ICU admission, and were 
more likely to require mechanical ventilation. No deaths 
were reported attributable to RSV. 
  The Spain case control study (IRIS study group) in in-
fants of 33 to 35 weeks gestational age linked to RSV related 
hospitalization (including 186 cases and 371 controls) re-
ported on a rate of 20.5% requiring ICU admission and 7.6% 
with need for mechanical ventilation [39]. During the study 
period no deaths were observed. Median length of stay in 
hospital was 8 days and in ICU 6 days. The IRIS study re-
ported on fifty-nine preterm infants below 33 weeks of ges-
tational age being rehospitalized for RSV infection of whom 
15 (25.4%) required ICU admission for a median of 6 (range 
3 to 11) days and three (5.1%) mechanical ventilation for a 
median of 5 (range 7 to 43) days [14]. 
  During a prospective study on infants younger than 24 
months hospitalized for viral upper and lower respiratory 
tract infection between November 1999 and October 2000 
we found 58 of 281 (21%) infants included being RSV posi-
tive by antigen detection in nasopharyngeal aspirates [9]. 
RSV positive infants were of younger age (mean 3.5 vs. 5.5 
months, p=0.003), had a higher lower respiratory illness 
score (ranging from 0 to 5; mean 2.9 vs. 1.8, p<0.001), and 
had more days of hospitalization, more days of oxygen   
requirement, and more days of respiratory support (all 
p<0.001, respectively). Comparison of RSV-positive U/LRTI 
of preterm with term infants showed differences only regard-
ing days of hospitalization (mean 14 vs 8.9; p = 0.007). 
Thus, RSV contributed to prolonged hospitalizations and 
more severe clinical courses of disease both in very young 
term and preterm infants. 
  Of 151 children under 1 year of age admitted to the pae-
diatric intensive care unit (PICU) of the Trousseau Hospital 
in Paris from 1 January 1996 to 31 December 2003 for man-
agement of bronchiolitis caused by proven RSV infection 
and requiring mechanical ventilation 14 infants (9.1%) 
needed extracorporeal membrane oxygenation (ECMO) sup-
port [40]. The frequency of BPD was significantly higher 
amongst children who required ECMO support as compared 
with those from the group without ECMO support (p=0.001, 
OR =8.9; 95%CI=2.4–33.1).  
  The rate for re-hospitalisation due to acute respiratory 
infection was 10.6% of 717 preterm infants (<35 weeks ges-
tational age) included in the Munich RSV study, and the risk 
for RSV related hospitalization was 5.2% during a one year 
observation period [10]. Preterm infants with BPD had a 
probability of 24.5% for rehospitalisation due to acute respi-
ratory infection and of 15% for RSV related hospitalization. 
The following factors were independently associated with an 
increased risk of RSV related hospitalization: male gender 
(adjusted OR: 8.7; 95% CI 2.6–29.1), chronic lung disease 
(OR: 3.99; 95%CI: 1.4–11.2), discharge between October 
and December (OR: 2.1; 95%CI: 0.99–4.4), and day-care 
attendance of siblings (OR: 3.9; 95%CI: 1.9–8.3). The me-
dian length of hospital stay was 8 days (range 2–48 days). 
Thirty-one infants (83.7%) were treated in regular pediatric 
wards, whereas six infants (16.2%) required intensive-care-
unit admission for a median duration of 6.5 days (range 4–8 
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  Assessing the effect of prematurity on RSV hospital re-
source use and outcomes by comparison of different gesta-
tional age-groups (<33, 33 to 35, and 36 weeks, respectively) 
resulted in higher intubation rates and longer stays at the 
hospital and the ICU in infants aged 33 to 35 weeks [41]. 
Infants 36 weeks gestational age had outcomes similar to 
term infants. Another study focusing on complications in 
infants hospitalized for RSV disease interestingly showed 
former preterm infants of 33 to 35 weeks gestational age 
having the highest rates of complications (93%), the longest 
mean hospital stay of 7.4 days and the highest costs out of 
the group with a history of prematurity [42].  
 Table  2 summarizes the published data on re-
hospitalization rates as a marker of severe RSV infection in 
preterm infants without BPD [10-14,24,38,39,43-52], and 
Table 3 those with BPD [10,12,14,35,44-46,53]. The mean 
RSV hospitalization rate of preterm infants was shown to be 
about 10% with a wide range from 0 to 44% (Alaska native 
children). This mean rate was significantly increased to 19% 
(p=0.016) in preterm infants with BPD (range 8.8 to 36.7%). 
Mortality 
  In children younger than 5 years and particularly in those 
aged under 1 year RSV is the most common viral cause of 
death, resulting in an estimated RSV-associated mortality 
rate of 3.2 per 100.000 person-years for the 1990/91 through 
1998/99 seasons in the United States [54]. A review of the 
literature revealed a RSV case fatality rate ranging from 0 to 
12% including 15 studies of developed countries and a rate 
ranging from 0 to 9.1% including 21 developing countries 
[55]. 
Table 3.  Rates of RSV Related Hospitalization (%) in Preterm 
Infants with Bronchopulmonary Dysplasia [10,12,14, 
35,44-46,53] 
Author, Year, Reference  Number of  
Patients (n) 
Hospitalization 
Rate (%) 
Groothuis, 1988 [35]  30  36.7 % 
Prevent Study, 1997 [44]  149  17.4 % 
IMpact Study 1998 [45]  266  12.8 % 
Stevens, 2000 [12]  131  25.2 % 
Thomas, 2000 [46]  34  8.8 % 
IRIS Study, 2000 [14]  53  15 % 
Greenough, 2001 [53]  235  19.1 % 
Liese, 2003 [10]  53  15 % 
 
  Over a study period covering eight consecutive RSV sea-
sons Thorburn [56] reported on 406 RSV-positive patients 
admitted to PICU. Eighteen patients died due to RSV   
bronchiolitis resulting in an ICU mortality rate of 4.4% and a 
Table 2.  RSV Related Hospitalization Rates for Preterm Infants Without Chronic Lung Disease/ Bronchopulmonary Dysplasia 
[10-14,24,38,39,43-52] 
Author, Year, Reference  Infants (n)  GA (weeks)  Chronologic Age (Months)  Hospitalization Rate (%) 
Nachmann 1997 [43]  1034  <2500 grams  <12  4.0 
PREVENT study 1997 [44]  510  35 <6  8.1 
IMpact study 1998 [45]  740  35  6 8.1 
Joffe 1999 [38]  1721  23-36  1st RSV season  3.2 
Carbonell 2000 [14]  584  32 <12 13.4 
Thomas 2000 [46]  48  < 32  1st RSV season  0-2.0 
Stevens 2000 [12]  1029  32  12 7.6 
Carbonell-Estrany 2001 [47]  999  32  1st RSV season  13.1 and 13.4 
McCormick 2002 [13]  1249  35 <52  6.4 
Pedraz 2003 [48]  1583  32  6 13.3 
Liese 2003 [10]  717  35 <12  5.2 
Pedersen 2003 [49]  240  <28 and/ or <1000grams  24 18.0 
Singleton 2003 [50]  N/A  <36  <12  43.9 
Law 2004 [51]  1832  33-35  1st RSV season  3.6 
Resch 2005 [24]  435  29-36  6 4.4 
Resch 2006 [11]  801  29-32  <24  4.5 
Doering 2006 [52]  1158  29-35  <12  4.2 
Figueras 2008 [39]  5441  32-35  6 3.7 140    The Open Microbiology Journal, 2011, Volume 5  Resch et al. 
total hospital RSV mortality rate of 1.7%. All of the RSV 
deaths were reported to have pre-existing medical conditions 
including chronic lung disease in 12%, but a history of   
prematurity was not predictive of death. 
  Sampalis [57] evaluated the impact of RSV infections on 
subsequent health care resource utilization in preterm in-
fants. Of data from 2415 preterm infants (32 to 35 weeks 
gestational age) hospitalized for proven or probable RSV and 
matched to 20,254 control infants the overall mortality rate 
was 8.1% for the RSV cohort and 1,6% for the controls 
(p<0.001). The author concluded that RSV hospitalization in 
healthy premature infants was associated with a significant 
increase in subsequent health care resource utilization and 
mortality.  
PREVENTION OF RSV INFECTION WITH PALIVI-
ZUMAB 
  In the early 1960s, vaccination of infants with a formalin-
inactivated RSV vaccine failed to be successful despite sig-
nificant increases of compliment fixatory antibodies in the 
vaccinated infants [58,59]. The vaccine augmented the sever-
ity of wild virus infection and led to the death of two infants 
in the following season. Standard polyclonal immunoglobu-
lin preparations containing substantial levels of neutralizing 
antibodies to RSV were not successful in the prevention of 
RSV hospitalisation. In contrast, the hyperimmmune RSV 
globulin (RespiGam
®) given intravenously at dosages of 750 
mg/kg monthly over the RSV season proved to be save and 
effective in prevention of lower respiratory tract infections in 
high-risk preterm infants and young children [60]. Children 
with cyanotic congenital heart disease however were more 
likely to experience adverse events, such as sudden unex-
plained death associated with cardiac surgery, if they re-
ceived RSV-IGIV. Thus, recommendations for the use of 
RSV-IGIV published by the American Academy of Pediat-
rics excluded those infants with CHD [61]. Despite its effi-
cacy, RSV-IGIV had the disadvantage of monthly infusions 
that were cumbersome, expensive, time-consuming, and 
stressful for both the patient and the parents, and there was 
always the remote possibility of blood-borne pathogen 
transmission. The development of a highly potent RSV-
neutralizing monoclonal antibody (Mab) was the next ap-
proach to improve the specific activity of anti-RSV immu-
noglobulin. In 1997, researchers at MedImmune, Inc. devel-
oped a humanized murine monoclonal antibody called paliv-
izumab (Synagis
®) that recognizes a conserved neutralizing 
epitope at the “A” region on the F glycoprotein of RSV [62]. 
  In a randomized, placebo controlled (palivizumab:placebo 
2:1), double-blind, multicenter phase III trial including 139 
centers in the United States, Canada, and the United King-
dom 1502 young children with prematurity ( 35 weeks of 
gestation,  6 months of age) or bronchopulmonary dysplasia 
( 24 months of age, requiring medical treatment within the 
past 6 months for their chronic lung disease) were included 
during the 1996 to 1997 RSV season to receive 5 monthly 
(every 30 days) injections of either 15 mg/kg palivizumab or 
an equivalent volume of placebo intramuscularly [45]. Chil-
dren were followed 150 days for the primary endpoint hospi-
talization due to RSV infection. Ninety-nine percent of the 
children in both groups completed the study protocol and 
93% received all five scheduled injections. Palivizumab pro-
phylaxis resulted in a 55% reduction in hospitalization as a 
result of RSV infection. Details of study results including 
secondary outcome measures are presented in Table 4 [45]. 
  The incidence of RSV related hospitalization following 
palivizumab prophylaxis was assessed in several retrospec-
tive and prospective studies conducted in Europe and North 
America [63]. In general, the incidence of RSV related hos-
pital admissions after palivizumab prophylaxis in post-
marketing surveillance studies was lower than the reported 
Table 4.  Results from the IMpact Study, a Randomized Placebo Controlled Trial on Palivizumab in Preterm Children with and 
Without Bronchopulmonary Dysplasia [45] 
RSV Hospitalization  Palivizumab 
n = 1002 
Placebo 
n = 500 
Relative Reduction (%)  p-Value* 
Preterm infants  35 weeks (including BPD)  4.8 %  10.6 %  55%  <0.001 
Preterm infants  35 weeks (no BPD)  1.8 %  8.1 %  78%  <0.001 
all BPD  7.9 %  12.8 %  39%  0.038 
Preterm infants 32-35 weeks (no BPD)  1.8 %  10.0 %  82%  <0.001 
Total days hospitalization/ 100 children  36.4  62.6  -  <0.001 
Total days with supplemental oxygen  30.3  50.6  -  <0.001 
Total days with LRI-score  3  29.6  47.4  -  <0.001 
ICU admission  1.3 %  3%  -  0.026 
Total ICU days  12.7  13.3  -  0.023 
Mechanical ventilation  0.2 %  0.7 %  -  0.280 
Total days of mechanical ventilation  1.7  8.4  -  0.210 
BPD = bronchopulmonary dysplasia, LRI-score = lower respiratory tract infection score (0 = no illness, 5 = mechanical ventilation), ICU = intensive care unit 
* Fisher´s exact test RSV and Prematurity  The Open Microbiology Journal, 2011, Volume 5    141 
rates of the IMpact study [46]. Data from the American 
Palivizumab Outcomes Registry provide the largest data   
set available on infants born prematurely with or without 
BPD and children with CHD (55-58) and are summarized in 
Table 5 [64].  
  Data from the French Pediatricians' Group of Synagis 
Patients' Name-Based Programs reported on 7.6% re-
hospitalisation rate in a population of 515 infants with a high 
rate of 81% of the infants included having BPD [65]. In the 
large Spanish trial of the IRIS Study Group [48] including 
two study cohorts of a total of 3502 infants over four RSV 
seasons (1998 to 2002) an overall reduction of 70% of RSV 
related hospital admissions in premature infants with and 
without BPD was demonstrated. Infants without prophylaxis 
had a 4-fold increased risk of RSV hospitalization. No deaths 
were reported in palivizumab recipients. 
  Adherence to the monthly injections scheme of palivizu-
mab prophylaxis remains a major problem. Parnes et al., [66] 
noted lower re-hospitalisation rates in infants with higher 
adherence to this scheme, and they observed that approxi-
mately half of RSV related hospitalizations occurred be-
tween the first and second injection. Similar findings were 
also reported by Manzoni et al., [67], consistent with the 
trends of serum palivizumab levels that may still be inade-
quate and not fully prototective after the first monthly dose 
[68]. Missed or delayed palivizumab injections resulted in an 
increase of RSV related hospitalizations from 2.4 % to 4.4 % 
(p=0.02). In comparison of a home versus office setting dur-
ing the 2000/2001 season 969 infants received palivizumab 
injections at home by a nurse and 477 in the office of a   
pediatrician [69]. Comparing home versus office, compliance 
was 98% compared with 89% (p<0.001), and RSV   
related hospitalization rate was 0.93% compared with   
3.57% (p<0.001). During a multicenter observational study 
of respiratory syncytial virus-associated hospitalizations and 
use of palivizumab in premature infants aged 29-32 weeks 
over two RSV seasons (2001 to 2003) in Austria 238 infants 
received palivizumab prophylaxis [11]. The rate of inade-
quate or incomplete injections was very high (62%) resulting 
in an increased rehospitalisation rate of 8.1% compared with 
3.3% of adequate prophylaxis (12/148 vs. 3/90, p=0.07). 
CONCLUSION 
  A vaccine for RSV is needed, and a protective live at-
tenuated vaccine administered at or around birth would be 
ideal. However, problems like insufficient attenuation of the 
vaccine strain of RSV, its thermolability, and the need to 
include A and B strains in each vaccine have hindered trials 
in infants under 3 months of age [4]. Prevention of RSV re-
lated hospitalizations in preterm infants by monthly injec-
tions of monoclonal antibodies like palivizumab or in the 
near future motavizumab is recommended in selected high-
risk groups [70] but still discussed due to the high costs of 
the product. Recent studies focused on RSV risk factor mod-
els aiming to tailor prophylactic treatment with monoclonal 
antibodies to those preterm infants with the highest risk for 
severe RSV related disease [71-74]. Until a vaccine is devel-
oped efforts to offer prophylaxis to high-risk infants is man-
datory. 
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